Search
BCPE Perseus Investor Ord Shs (Proposed)
KLRAAdd to Watchlist
23.170USD
+0.230+1.00%
Close 06/01, 16:00（ET）Quotes delayed by 15 min
2.97BMarket Cap
--P/E TTM
More Details of BCPE Perseus Investor Ord Shs (Proposed) Company
Kailera Therapeutics Inc is a United States-based company. The Company is a clinical-stage biopharmaceutical company developing a broad and advanced therapeutic pipeline that is poised to deliver differentiated treatment options for obesity and related conditions. Its pipeline consists of clinical- and preclinical-stage programs with injectable peptides, oral peptides, and an oral small molecule.
BCPE Perseus Investor Ord Shs (Proposed) Info
Ticker SymbolKLRA
Company nameKailera Therapeutics Inc
IPO dateApr 17, 2026
CEORenaud (Ron)
Number of employees- -
Security typeOrdinary Share
Fiscal year-end- -
Address180 Third Ave
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02451
Phone15084409475
Websitehttps://www.kailera.com
Ticker SymbolKLRA
IPO dateApr 17, 2026
CEORenaud (Ron)
Company Executives of BCPE Perseus Investor Ord Shs (Proposed)
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Mr. Ron Renaud
Mr. Ron Renaud
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul Burgess
Mr. Paul Burgess
Chief Operating Officer, Chief Business Officer
Chief Operating Officer, Chief Business Officer
--
--
Ms. Paula Cloghessy
Ms. Paula Cloghessy
Chief People Officer
Chief People Officer
--
--
Mr. Scott M. Akamine, J.D.
Mr. Scott M. Akamine, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Ms. Jamie Coleman
Ms. Jamie Coleman
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Douglas W. Pagan
Mr. Douglas W. Pagan
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Scott Wasserman, M.D.
Dr. Scott Wasserman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Franklin K. (Frank) Clyburn, Jr.
Mr. Franklin K. (Frank) Clyburn, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Mr. Ron Renaud
Mr. Ron Renaud
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul Burgess
Mr. Paul Burgess
Chief Operating Officer, Chief Business Officer
Chief Operating Officer, Chief Business Officer
--
--
Ms. Paula Cloghessy
Ms. Paula Cloghessy
Chief People Officer
Chief People Officer
--
--
Mr. Scott M. Akamine, J.D.
Mr. Scott M. Akamine, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Ms. Jamie Coleman
Ms. Jamie Coleman
Chief Commercial Officer
Chief Commercial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Apr 29
Updated: Wed, Apr 29
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bain Capital Private Equity, LP
20.27%
Bain Capital Life Sciences Investors, LLC
17.43%
Other
62.30%
Shareholders
Shareholders
Proportion
Bain Capital Private Equity, LP
20.27%
Bain Capital Life Sciences Investors, LLC
17.43%
Other
62.30%
Shareholder Types
Shareholders
Proportion
Private Equity
20.27%
Investment Advisor
17.43%
Other
62.30%
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Reporting Period
No. of institutions
Shares Held
Proportion
Change
No Data
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
No Data
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
